• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    BriaCell Validates Bria-OTS+™ Mechanism in Top Cancer Journal

    GLOBENEWSWIRE

    BriaCell Secures $2M NCI Grant for Bria-PROS+™ in Prostate Cancer

    GLOBENEWSWIRE

    BriaCell Sets Date for Share Consolidation Proposal

    GLOBENEWSWIRE

    BriaCell Selected for MSK 2025 Cancer Accelerator Program

    GLOBENEWSWIRE

    BriaCell Announces Proposed Effective Date of Share Consolidation

    GLOBENEWSWIRE

    BriaCell Includes UCLA Health in Phase 3 Breast Cancer Study

    GLOBENEWSWIRE

    BriaCell Receives New Zealand Patent for Whole Cell Tech

    GLOBENEWSWIRE

    BriaPro Files Patent for Immuno-Oncology Multitargeting Agents

    GLOBENEWSWIRE

    Bria Cell Presents Two Clinical Data Posters at ESMO 2025

    GLOBENEWSWIRE

    BriaCell Therapeutics Closes $15M Public Offering

    GLOBENEWSWIRE

    BriaCell Includes Mayo Clinic in Phase 3 Breast Cancer Study

    GLOBENEWSWIRE

    BriaCell Announces $15M Public Offering Pricing

    GLOBENEWSWIRE

    Bria-IMT Outperforms Trodelvy in Metastatic Breast Cancer

    GLOBENEWSWIRE

    BriaCell Reports Full Brain Metastasis Resolution in Patient

    GLOBENEWSWIRE

    BriaCell Patient Shows Complete Lung Metastasis Resolution Study

    GLOBENEWSWIRE

    BriaCell: 52% Breast Cancer Patients Pass One-Year Mark

    GLOBENEWSWIRE

    BriaCell Adds Phase 3 Sites in Los Angeles and Yale Hospital

    GLOBENEWSWIRE

    BriaCell Gets DSMB Green Light for Ph 3 Breast Cancer Trial

    GLOBENEWSWIRE

    BriaCell to Hold Virtual Investor Presentations on June 12 & 26

    GLOBENEWSWIRE

    BriaCell Reports Strong Data at ASCO 2025

    GLOBENEWSWIRE

    BriaCell Doses 1st Patient in Bria-OTS Ph1/2 Safety Study

    GLOBENEWSWIRE

    BriaCell Abstracts Positive Data at ASCO 2025

    GLOBENEWSWIRE

    BriaCell CEO Letter to Shareholders

    GLOBENEWSWIRE

    BriaCell Reports Positive Phase 3 Data at AACR 2025

    GLOBENEWSWIRE

    BriaCell Shows Survival and Clinical Benefit at AACR 2025

    GLOBENEWSWIRE

    BriaCell Therapeutics Closes $13.8M Public Offering

    GLOBENEWSWIRE

    BriaCell Therapeutics Prices $13.8M Public Offering

    GLOBENEWSWIRE

    BriaCell Announces Four Clinical Data Presentations at ASCO 2025

    GLOBENEWSWIRE

    BriaCell Ph 3 Study Enrollment Accelerating in (Bria-ABC) Cancer

    GLOBENEWSWIRE

    BriaCell Phase 2 Data Beats Standard in HR+ Breast Cancer

    GLOBENEWSWIRE

    BriaCell`s BriaPro Develops Antibodies for Cancer Target B7-H3

    GLOBENEWSWIRE

    BriaCell to Present Data at 2025 AACR Conference

    GLOBENEWSWIRE

    Second Board Recommends Continuing BriaCell’s Phase 3 Breast Cancer

    GLOBENEWSWIRE

    BriaCell Therapeutics Announces Closing of Public Offering

    GLOBENEWSWIRE

    BriaCell Therapeutics Corp Announces Result of Shareholder Meeting

    GLOBENEWSWIRE

    BriaCell Therapeutics Announces Public Offering of Common Shares

    GLOBENEWSWIRE

    BriaCell Therapeutics Announces Pricing of Public Offering

    GLOBENEWSWIRE

    BriaCell Announces Resolution of Lung Metastasis in 1st Patient

    GLOBENEWSWIRE

    BriaCell Announces Completion of 15:1 Share Consolidation

    GLOBENEWSWIRE

    BriaCell Announces Proposed Effective Date of Share Consolidation

    GLOBENEWSWIRE

    BriaCell Announces Rescheduling of Annual Meeting to Feb 5, 2025

    GLOBENEWSWIRE

    BriaCell Announces AGM Materials & Voting Procedures Availability

    GLOBENEWSWIRE

    BriaCell 2024 SABCS® Poster Highlights Bria-IMT™ Benefits

    GLOBENEWSWIRE

    BriaCell Closes $5.5M Public Offering Successfully

    GLOBENEWSWIRE

    BriaCell Presents Data in Metastatic Breast Cancer at SABCS

    GLOBENEWSWIRE

    BriaCell Therapeutics Announces Proposed Public Offering

    GLOBENEWSWIRE

    BriaCell Therapeutics Prices $5.5 Million Public Offering

    GLOBENEWSWIRE

    BriaCell to Present SABCS® Spotlight Poster on Breast Cancer

    GLOBENEWSWIRE

    BriaCell Provides Update to its Board of Directors

    GLOBENEWSWIRE

    BriaCell Doses First Patient in Metastatic Breast Cancer Study

    GLOBENEWSWIRE

    BriaCell Showcases Off-the-Shelf Immunotherapy at SITC 2024

    GLOBENEWSWIRE

    BriaCell’s Overall Survival Data Selected for SABCS 2024 Spotlight

    GLOBENEWSWIRE

    BriaCell Reports Survival Data For Metastatic Breast Cancer

    GLOBENEWSWIRE

    BriaCell Provides Phase 3 Clinical Update In Metastatic Breast Cancer

    GLOBENEWSWIRE

    BriaCell Therapeutics Announces Closing of $5 Million Offering

    GLOBENEWSWIRE

    BriaCell Therapeutics Announces $5 Million Offering

    GLOBENEWSWIRE

    BriaCell Announces FDA-Authorized Expanded Access Policy

    GLOBENEWSWIRE

    BriaCell Therapeutics Announces Closing of $8.5 Million Offering

    GLOBENEWSWIRE

    BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer

    GLOBENEWSWIRE

    BriaCell Therapeutics Announces $8.5 Million Offering

    GLOBENEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.